Novo Nordisk Signs an Exclusive Worldwide License Agreement with UBE Industries for its UD-014

 Novo Nordisk Signs an Exclusive Worldwide License Agreement with UBE Industries for its UD-014

Novo Nordisk Signs an Exclusive Worldwide License Agreement with UBE Industries for its UD-014

Shots:

  • UBE to receive up front, development & commercial milestones and royalties on sales. Novo Nordisk to get exclusive WW license to UBE’s preclinical asset UD-014 and will be responsible for development, manufacturing and commercialization of UD-014
  • The collaboration will widen Novo Nordisk’s presence and investment in NASH and will provide more treatment options to the patients living with NASH
  • UBE’s UD-014 is a selective semi carbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1) inhibitor, demonstrating efficacy in preclinical studies for its anti-inflammatory MOA and antioxidative effect on endothelial cells, potentially used for NASH

Click here to­ read full press release/ article | Ref: UBE | Image: The Local Denmark

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post